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Apoptosisa b s t r a c t
Hepatocellular carcinoma downregulated 1 (HEPN1), a cell growth arrest- and apoptosis-related
gene, is suppressed in hepatocellular carcinoma (HCC). However, transcriptional control of HEPN1
has not been characterized. Here, we show that exposure to reactive oxygen species (ROS) leads to
upregulation of the mRNA expression of HEPN1 in HCC cell lines. Mechanistically, ROS increase pro-
duction of an alternately spliced form of X-box binding protein 1 (XBP1s) and XBP1s increases
HEPN1 expression by binding to the HEPN1 promoter, thereby acting as a transcriptional activator.
Finally, HEPN1 overexpression increases the expression of p53, p21, and Bax, all of which are ROS-
upregulated proteins.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction leading to DNA damage and improper protein folding, andHepatocellular carcinoma downregulated 1 (HEPN1) is a small
protein that consists of 88 amino acids [1]. HEPN1 is located on
the opposite strand of the 30-non-coding region of hepatocyte cell
adhesion molecule (HEPACAM), and it induces cell growth arrest
and apoptosis in human, mouse, and rat cell lines [1–3]. To date,
HEPN1 has not been well characterized functionally and its protein
and DNA homologues have not been identiﬁed [1,2]. Moreover, the
mechanisms that control HEPN1 expression have not been
characterized.
Reactive oxygen species (ROS) act as second messengers to reg-
ulate various signaling pathways [4–8]. The role of ROS differs
depending on concentration and localization [4,8–10]. At moderate
concentrations, ROS stimulate cell proliferation and survival func-
tions by activating the Ras, phosphatidylinositide 3-kinase (PI3K),
nuclear factor-kappa B (NF-jB), and Wnt signaling pathways [9–
13]. At high concentrations, ROS cause oxidative stress, therebysubsequently induce endoplasmic reticulum (ER) stress, cell cycle
arrest, senescence, and apoptosis [9,10,14]. ROS are also an
important factor in carcinogenesis because the consistent
accumulation of ROS causes abnormal cell proliferation and DNA
mutations [5,15].
X-box binding protein 1 (XBP1) is a transcription factor that
regulates major histocompatibility complex (MHC) I-related gene
expression by binding to the X2 site, which is located between
the X-box and the spacer site of the HLA-DRA and HLA-DPB gene
promoters [16,17]. In addition, XBP1 binds to ER stress response
element (ESRE)-like sequences along with other transcription fac-
tors, such as nuclear transcription factor Y (NF-Y), to regulate the
expression of ER stress-related genes [18]. Conventional XBP1
mRNA encodes the XBP1u protein that consists of 294 amino acids
and lacks a transcription activation domain (TAD) [19]. However,
the activation of inositol requiring enzyme 1 (IRE1) via ROS and
ER stress causes IRE1-induced cytoplasmic alternative splicing of
XBP1 mRNA, producing a frame shift that results in the production
of a spliced mRNA that encodes the XBP1s protein. XBP1s consists
of 430 amino acids, contains a TAD, and can activate target gene
expression [19,20].
In this study, we show that exposure to ROS upregulates HEPN1
expression in hepatocellular carcinoma (HCC) cell lines.
Furthermore, we reveal that ROS-induced upregulation of the
XBP1s transcription factor increases HEPN1 promoter activity.
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2.1. Cell culture and treatments
The human Huh7 (hepatoma), Hep3B (hepatoma), and HepG2
(hepatoblastoma) cell lines were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). The human THLE-3 (immortalized normal liver cells)
cell line was cultured in Bronchial Epithelial Cell Growth Medium
(BEGM) supplemented with 10% FBS, 5 ng/ml epidermal growth
factor, and 70 ng/ml phosphoethanolamine. In some experiments,
the cells were incubated with 300 lM H2O2 for 24 h. For siRNA
experiments, cells were transfected with XBP-1 siRNA (h): sc-
38627 or control siRNA (Santa Cruz Biotechnology Inc.) using Oli-
gofectamine (Invitrogen). Unless otherwise noted, the reagents
were obtained from Sigma.
2.2. Plasmids
Human HEPN1, XBP1s, and XBP1u cDNAs were obtained from
THLE-3 cell line and cloned into pCMV/HA and/or pCMV/Myc
(Clontech) expression vectors. Human HEPN1 promoter genomic
DNA was obtained from THLE-3 cell line and cloned into pGL3-
basic (Promega) luciferase reporter vector. DNA Using pGL3-
HEPN1 promoter 999 to +1 as a template, serial deletion and
point mutation promoter constructs were developed by site-direc-
ted mutagenesis.
2.3. Antibodies
Mouse monoclonal anti-HEPN1 antibody (sc-138338, Santa
Cruz Biotechnology Inc.), mouse monoclonal anti-p53 antibody
(sc-126, Santa Cruz Biotechnology Inc.), mouse monoclonal anti-
hsp90 antibody (sc-7947, Santa Cruz Biotechnology Inc.), mouse
monoclonal anti-hsp70 antibody (sc-24, Santa Cruz Biotechnology
Inc.), mouse monoclonal anti-hsp27 antibody (sc-13132, Santa
Cruz Biotechnology Inc.), goat polyclonal anti-grp78 antibody (sc-
1050, Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-
hypoxia-inducible factor 1-alpha (HIF1a) antibody (sc-10790,
Santa Cruz Biotechnology Inc.), mouse monoclonal anti-Myc anti-
body (sc-40, Santa Cruz Biotechnology Inc.), rabbit polyclonal
anti-p21 antibody (#2947, Cell Signaling Technology Inc.), rabbit
polyclonal anti-Bax antibody (#2772, Cell Signaling Technology
Inc.), rabbit polyclonal anti-catalase antibody (ab1877, Abcam),
and mouse monoclonal anti-b-actin antibody (A5441, Sigma) were
used in the study.2.4. Promoter analysis
To analyze promoter activity, luciferase assays were performed
with the HEPN1 promoters. Cells were plated at 1.5  105 cells/ml
in 6-well plates one day before transfection. Non-liposomal-medi-
ated gene transfer was performed using FuGENE6 (Roche) accord-
ing to the manufacturer’s instructions, using 1 lg of DNA
consisting of the reporter construct, expression vectors, or the
internal control vector. Forty-eight hours after transfection, cells
were analyzed for luciferase activity using the Dual-Luciferase
Reporter Assay (Promega) following the manufacturer’s instruc-
tions and quantiﬁed with a Luminoskan Ascent Luminometer
(Thermo LabSystems).
2.5. Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were performed
as described [21]. In all cases, chromatin was sheared to an averagelength of 0.4–1 kilobase (kb) using Bioruptor (CosmoBio Co Ltd,
Tokyo, Japan). Immunoprecipitations of cross-linked chromatin
were carried out with commercial antibodies. PCR products were
ampliﬁed with speciﬁc primers for HEPN1 promoters. PCR ampliﬁ-
cation was normalized to DNA collected after sonication (input
fraction).
2.6. Immunoblot analysis
Cell lysates were prepared and analyzed by immunoblots as
previously described [22]. Band intensity was determined using
the ImageMaster 2D Elite software 4.01 (Amersham, Upsala, UK).
2.7. Reverse transcription PCR and quantitative real-time PCR analysis
Reverse transcription PCR and quantitative real-time PCR anal-
ysis of cDNA samples was performed using speciﬁc primers
designed using Primer Express software (Applied Biosystems, Fos-
ter City, CA). Primers for HEPN1: 50-ATGGGTAACTGGGGCCTTGG-30
(forward) and 50-TCACACTAACATCAAAATAAAGAG-30 (reverse);
primers for XBP1: 50-CAGCAGGTGCAGGCCCAGTT-30 (forward) and
50-GGGGCTTGGTATATATGTGG-30 (reverse); and primers for XBP1s:
50-CCTTGTAGTTGAGAACCAGG-30 (forward) and 50-GGGGCTTGGTA
TATATGTGG-30 (reverse). Total RNA was extracted from cultured
cells by using an RNeasy kit (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. cDNA was synthesized using 1 lg
RNA with AMV reverse transcriptase (Promega, Madison, WI) and
oligo-dT primers. Band intensity was determined using the Image-
Master 2D Elite software 4.01 (Amersham, Upsala, UK) and tran-
script levels were assessed by quantitative real-time PCR (qRT-
PCR, ABI 7300, Applied Biosystems). All experiments were normal-
ized to b-actin.2.8. Statistical analysis
Data in bar graphs are expressed as the mean ± standard devia-
tion of three independent experiments. All results in the bar graphs
are expressed as the fold ratio relative to untreated or control cells.
Statistical analysis was performed using SPSS statistics software
(Ver. 19, SPSS Inc. Chicago, IL).3. Results
3.1. H2O2 increases the expression and promoter activity of HEPN1
To investigate expression changes initiated by ROS in unknown
genes, we administered 300 lMH2O2 to THLE-3 and Hep3B cells to
increase their ROS levels, and analyzed the resulting changes in the
whole transcriptome using a suppression subtractive hybridization
assay [8,23]. We found that HEPN1 was a candidate ROS-upregu-
lated gene.
Next, we administered 300 lM H2O2 to Huh7, Hep3B, and
THLE-3 cells and analyzed changes in HEPN1 mRNA levels by
reverse transcription PCR (RT-PCR). H2O2 treatment induced
upregulation of HEPN1 expression by 2.09-, 1.39-, and 2.77-fold
in Huh7, Hep3B, and THLE-3 cells, respectively (Fig. S1A). In addi-
tion, we pretreated cells with 5 mM N-acetyl-L-cysteine (NAC), an
ROS scavenger, for 1 h, followed by 300 lM H2O2 treatment to
Huh7, Hep3B, and THLE-3 cells and analyzed changes in HEPN1
mRNA levels by quantitative real-time PCR (qRT-PCR) and HEPN1
protein levels by immunoblotting. H2O2 treatment increased
HEPN1 mRNA and protein expression, but NAC pretreatment abol-
ished the upregulation of HEPN1 expression (Fig. 1A and B).
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human HEPN1 promoter was cloned into the pGL3-basic vector. A
reporter gene assay showed that H2O2 increased the transcriptional
activity of the HEPN1 promoter in all three cell lines, but pretreat-
ment with NAC abolished H2O2-induced upregulation of HEPN1
promoter activity (Fig. 1C). In addition, HEPN1 expression and
HEPN1 promoter activity were increased by H2O2 treatment in
dose- and time-dependent manners (Fig. S1B and C)
3.2. ROS affect the XBP1-associated site of the HEPN1 promoter
To investigate how ROS upregulate HEPN1 transcription, we
screened the HEPN1 promoter sequence using the PROMO, TFBIND,
and TFSEARH databases [24–26]. We then analyzed the potential
ROS-related transcription factor-binding sites and identiﬁed four
XBP1-binding sites (XBP1 site #1 to #4) with high binding scores
in the HEPN1 promoter (Fig. 2A).
A series of mutated plasmids harboring different regions of the
HEPN1 promoter were constructed based on these XBP1 sites
(Fig. 2B). A reporter gene assay indicated that the 350 to +1 pro-
moter region is required for ROS-induced HEPN1 transcriptional
activation (Fig. 2C). Furthermore, two point-mutated plasmids har-
boring different XBP1-binding regions of the HEPN1 promoter wereFig. 1. ROS increase HEPN1 expression in HCC and normal liver cells. (A and B) Huh7, He
300 lMH2O2 for 24 h. HEPN1mRNA (A) and HEPN1 protein (B) expression were analyzed
(C) Huh7, Hep3B, and THLE-3 cells were transfected with pGL3-HEPN1 promoter 999
300 lM H2O2 for 24 h and analyzed for luciferase activity. Data in bar graphs representconstructed (Fig. 2B). The reporter gene assay indicated that XBP1
site #3 is critical for ROS-induced HEPN1 transcriptional activation,
while XBP1 site #4 is not (Fig. 2D). Thus, it appears that ROS
increase HEPN1 expression by affecting the XBP1 site #3 of the
HEPN1 promoter.
3.3. ROS-induced XBP1s upregulation increases HEPN1 expression
To investigate whether the XBP1 site #3 has a reliable and capa-
ble XBP1 binding sequence, we analyzed the predicted XBP1 sites
#1 to #4 and compared them with the X2 sequence of the HLA-
DPB gene [17]. Interestingly, we identiﬁed an 8-bp sequence in
XBP1 site #3 that is identical to the 8-bp X2 sequence of HLA-
DPB, which interacts with XBP1 (Fig. 3A).
Collectively, these data indicate that XBP1 may be the HEPN1
promoter-binding factor and the cause of ROS-induced HEPN1
upregulation. The conventionally expressed XBP1 protein (XBP1u)
has no transcriptional activity, whereas the alternatively spliced
form of XBP1 protein (XBP1s) does [19]. Therefore, we performed
an alternatively spliced XBP1-speciﬁc RT-PCR, and expression of
XBP1s was increased by H2O2 treatment in HCC cell lines (Fig. 3B).
Next, we transfected the XBP1s or XBP1u expression vector into
Huh7 and Hep3B cells and analyzed the resulting changes in HEPN1p3B, and THLE-3 cells were pretreated with 5 mM NAC for 1 h and then treated with
by qRT-PCR and immunoblotting, respectively. b-Actin served as an internal control.
to +1 vector (HP1.0) and/or pretreated with 5 mM NAC for 1 h and/or treated with
the mean ± standard deviation of three independent experiments.
Fig. 2. ROS increase the promoter activity of the HEPN1 gene. (A) Prediction of ROS-induced transcription factor binding to the HEPN1 promoter. (B) Schematic diagram of
deletion and point mutants of the HEPN1 promoter. (C) Huh7 and Hep3B cells were transfected with HEPN1 promoter serial deletion vectors fused to luciferase and/or treated
with 300 lM H2O2 for 24 h and analyzed for luciferase activity. (D) Huh7 and Hep3B cells were transfected with HEPN1 promoter point mutant vectors fused to luciferase
and/or treated with 300 lMH2O2 for 24 h and analyzed for luciferase activity. Data in bar graphs represent the mean ± standard deviation of three independent experiments.
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HEPN1 expression (Fig. 3C), while XBP1u did not alter HEPN1
expression (Fig. 3D). Furthermore, in H2O2-treatedHuh7 andHep3B
cells transfected with XBP1 siRNA, whole XBP1 and XBP1s mRNA
expression was decreased (Fig. S2A and B), and ROS-induced HEPN1
upregulationwas decreased compared to control siRNA-transfected
cells (Fig. 3E). Thus, it appears that the upregulation of ROS-induced
XBP1 splicing increases HEPN1 expression.
3.4. XBP1s activates the transcription of the HEPN1 promoter
Because it is expected that XBP1s acts as a transcriptional acti-
vator of the HEPN1 promoter, a reporter gene assay was performed.
The results showed that in HCC cells, XBP1s increases the tran-
scriptional activity of the HEPN1 promoter, while XBP1u does not
(Fig. 4A and B).
Further, a reporter gene assay using serial deletion promoters
indicated that the 350 to +1 promoter region is required forXBP1s-induced HEPN1 transcriptional activation (Fig. 4C). A
reporter gene assay using point-mutated promoters indicated
that XBP1 site #3 is critical for XBP1s-induced HEPN1 transcrip-
tional activation, while XBP1 site #4 is not (Fig. 4D). Thus, XBP1s
increases HEPN1 expression via upregulation of HEPN1 promoter
activity.
3.5. XBP1s binds to the HEPN1 promoter in HCC cells
To verify whether XBP1s binds to the endogenous HEPN1
promoter, chromatin immunoprecipitation (ChIP) assays were per-
formed. When ChIP assays were performed using a Myc-tag anti-
body to precipitate Myc-XBP1s and its interactants, target DNA
bands were detected by a PCR assay with endogenous HEPN1 pro-
moter-speciﬁc probes in Huh7 and Hep3B cells (Fig. 5A). These
data reveal that XBP1s binds to the endogenous HEPN1 promoter.
To verify whether XBP1s directly binds as predicted to XBP1 site
#3 of the HEPN1 promoter, ChIP assays were performed using
Fig. 3. XBP1s increases HEPN1 expression in HCC cells. (A) Alignment result of XBP1 sites #1 to #4 of the HEPN1 promoter and the X2 site of the HLA-DPB promoter. (B) Huh7
and Hep3B cells were treated with 300 lM H2O2 for 24 h. Whole XBP1mRNA and alternatively spliced XBP1mRNA expression were analyzed by RT-PCR. b-Actin served as an
internal control. (C) Huh7 and Hep3B cells were transfected with an XBP1s expression vector for 48 h. HEPN1mRNA expression was analyzed by RT-PCR (left panel) and qRT-
PCR (right panel). b-Actin served as an internal control. (D) Huh7 and Hep3B cells were transfected with XBP1u expression vector for 48 h. HEPN1 mRNA expression was
analyzed by RT-PCR (left panel) and qRT-PCR (right panel). b-Actin served as an internal control. (E) Huh7 and Hep3B cells were treated with 300 lM H2O2 for 24 h and/or
transfected with XBP1 siRNA for 48 h. HEPN1 mRNA expression was analyzed by qRT-PCR. b-Actin served as an internal control. Data in bar graphs represent the
mean ± standard deviation of three independent experiments.
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showed that XBP1s bound to the 999 to +1 and 350 to +1
regions of the HEPN1 promoter and to HEPN1 promoter mut #2
(HPmut2), but not to HEPN1 promoter mut #1 (HPmut1)
(Fig. 5B). Collectively, these data suggest that XBP1s directly binds
to the 67 to 62 region of the HEPN1 promoter, XBP1 site #3, and
acts as a transcriptional activator.3.6. HEPN1 upregulates p53, p21, and Bax expression, similar to ROS
Previous reports demonstrated that HEPN1 suppresses cell
growth and induces apoptosis [1,2]. In addition, ROS are known
to arrest the cell cycle and upregulate apoptosis signaling
[10,14]. To investigate which proteins among the oxidative
stress-, cell cycle arrest-, and apoptosis-related proteins (all of
Fig. 4. XBP1s increases the promoter activity of the HEPN1 gene. Huh7 and Hep3B cells were transfected with the pGL3-HP1.0 vector and either the (A) XBP1s or the (B)
XBP1u expression vectors for 48 h and analyzed for luciferase activity. (C) Huh7 and Hep3B cells were transfected with HEPN1 promoter serial deletion vectors fused to
luciferase and/or XBP1s expression vector for 48 h and analyzed for luciferase activity. (D) Huh7 and Hep3B cells were transfected with HEPN1 promoter point mutant vectors
fused to luciferase and/or XBP1s expression vector for 48 h and analyzed for luciferase activity. Data in bar graphs represent the mean ± standard deviation of three
independent experiments.
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performed an immunoblotting assay using antibodies for Myc-
tag (Myc-HEPN1), HEPN1, p53, p21, Bax, catalase, hsp90, hsp70,
hsp27, grp78, and HIF1a.
ROS are known to upregulate the expression of p53, p21, Bax,
catalase, hsp70, and HIF1a [27–33]. HEPN1 upregulated the
expression of p53, p21, and Bax, all of which are related to cell
cycle arrest and apoptosis, in HepG2 cells carrying wild type
p53, but not in Huh7 or Hep3B cells carrying mutant or null
p53 (Fig. 6A). In addition, the viability of HepG2, Huh7, andHep3B cells was examined by an MTT assay 0–3 days after trans-
fection with pCMV/Myc (control) or pCMV/Myc-HEPN1. Cell
growth was suppressed in Myc-HEPN1-transfected HepG2 cells
compared with control HepG2 cells. However, the viability of
Huh7 and Hep3B cells was not affected by Myc-HEPN1 transfec-
tion (Fig. 6B).
Furthermore, to identify how HEPN1 activates the apoptosis
pathway, we used a Human Apoptosis Signaling Pathway RT2
Proﬁler™ PCR Array (SABiosciences Corporation) comparing
transcript levels between the control and HEPN1-expressing
Fig. 5. XBP1s binds to HEPN1 promoter. (A) Huh7 and Hep3B cells were transfected with the Myc-XBP1s expression vector for 48 h. ChIP analysis of the endogenous HEPN1
promoter was performed. IgG was used as a negative control. (B) Huh7 and Hep3B cells were transfected with the Myc-XBP1s expression vector and the serial deletion
mutants, or the XBP1-binding site mutant HEPN1 promoters fused to luciferase for 48 h. ChIP analysis of HEPN1 promoters in transfected cells was performed. IgG was used as
a negative control. Results shown are representative of three independent experiments.
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of 83 genes involved in the apoptosis pathway (Table S1).
Sixteen genes were upregulated more than 2.5-fold by HEPN1.
Among the 16 upregulated genes, there were 8 apoptosis-
induced genes: FASLG, LTA, TNFSF8, CD70, TNF, TNFRSF9,
GADD45A, BIK; 4 caspases: CASP5, CASP14, CASP10, CASP1; 2
DEATH and CARD domain proteins: TNFRSF11B, CARD6; and 2
anti-apoptosis genes: BIRC8, BCL2L10 (Fig. 6C). Collectively, these
data indicate that HEPN1 may be involved in the ROS-induced
cell growth arrest pathway.
4. Discussion
In this study, several mechanisms regulating HEPN1 expression
were identiﬁed. First, the expression level of HEPN1 mRNA was
upregulated by ROS; second, XBP1s, which was also upregulated
by ROS, acted as a transcriptional activator of the HEPN1 promoter;
and third, HEPN1 increased cell growth arrest and apoptosis sig-
nals in HepG2 cells carrying wild-type p53. These results suggest
that ROS upregulate HEPN1 transcription levels by increasing the
alternative splicing of XBP1; accordingly, these factors seem to
be involved in a pathway that induces cell growth arrest and
apoptosis.
As shown in our previous study, when HCC cells are exposed to
high levels of ROS, the invasiveness of HCC cells is increased
through the upregulation of the transcriptional repressor Snail, a
thereby suppressing the expression of E-cadherin [21]. In addition,
Notch1 and ROS-induced PI3K/Akt signals cooperatively increase
the protein level of Snail in HCC cells [34]. Our previous study also
demonstrated that the expression of catalase and the OCT1 tran-
scription factor is downregulated as a result of increased CpG
island DNA methylation [35,36]. Considering the increased Snailexpression and decreased catalase and OCT1 expression observed
in HCC tissues displaying high ROS levels, we believe that ROS is
an important factor for HCC progression.
In HCC cells, the expression of HEPN1 is upregulated by ROS, but
the expression of HEPN1, along with that of the opposite strand
gene HEPACAM, is suppressed in HCC tissues [1,3]. Therefore, we
infer that factors other than ROS levels may suppress the expres-
sion HEPN1 in HCC tissues. However, the cause of the suppression
remains unknown because of a lack of data regarding the regula-
tion of HEPN1 expression. In addition, HEPN1 has not been com-
pletely functionally characterized as compared to HEPACAM,
which is known to be involved in cell–cell interactions in hepato-
cytes and glial cells [3].
Our study demonstrates that XBP1 alternative splicing is
increased via ROS-induced ER stress signaling and that the
upregulated XBP1s acts as a transcriptional activator of HEPN1,
thereby increasing HEPN1 expression. Among the ROS-regulated
proteins p53, p21, Bax, catalase, hsp90, hsp70, hsp27, grp78,
and HIF1a, HEPN1 upregulates the expression of p53, p21, and
Bax, proteins that are related to cell cycle arrest and apoptosis.
This upregulation occurs in HepG2 cells carrying wild-type p53,
but not in Huh7 and Hep3B cells carrying mutant p53. In
addition, HEPN1 also decreases cell viability in HepG2 cells, but
not in Huh7 and Hep3B cells. Furthermore, HEPN1 upregulates
the transcription of 12 apoptosis-induced genes and 2 regulatory
genes, while upregulating only 2 anti-apoptosis genes. Taken
together, these data suggest that HEPN1 may be involved in
p53-associated ROS-induced cell growth arrest and the apoptosis
pathway.
Combined with the results of other studies, our results show
that HEPN1 is increased via ROS-induced upregulation of XBP1s
and acts as an inducer of cell growth arrest and apoptosis. With
Fig. 6. HEPN1 increases the expression of p53, p21, and Bax proteins and suppresses cell growth in HepG2 cells. (A) HepG2, Huh7, and Hep3B cells were treated with 300 lM
H2O2 or transfected with the Myc-HEPN1 expression vector. Immunoblot analysis of Myc-HEPN1, HEPN1 (endogenous), p53, p21, Bax, catalase, hsp90, hsp70, hsp27, grp78,
and HIF1a was performed using speciﬁc antibodies. b-Actin served as a loading control. Results shown are representative of three independent experiments. (B) HepG2,
Huh7, and Hep3B cells were transfected with the Myc-HEPN1 expression vector. Cell viability was measured by an MTT assay. Absorbance was read at 570 nm and is reported
as an average of triplicate wells. Results shown are representative of three independent experiments. (C) HepG2 cells were transfected with the control vector or the Myc-
HEPN1 expression vector for 48 h. The expression proﬁling of 84 apoptosis pathway-focused genes was performed using the RT2 Proﬁler PCR Array System. Results are shown
as the expression ratios between control/HEPN1-transfected HepG2 cells with a 2.5-fold change cut-off.
4420 H.S. Kim, G. Jung / FEBS Letters 588 (2014) 4413–4421this, the function and regulatory mechanism of HEPN1 in the
ROS-induced cell cycle arrest and apoptosis pathways require
further investigation. If the restoration of HEPN1 expression,which is suppressed in HCC, can be facilitated through further
study, we believe that it may be a potential HCC therapy
target.
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